Audible. Only £0.99 a month for the first 3 months + £10 Audible voucher. Pay £0.99 for the first 3 months, and £7.99/month thereafter. Renews automatically. Start my membership.

Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)
Nov 18 2024
Length: 14 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Listen for free

View show details

Summary
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration.

Related Content:

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
Show More Show Less

Show More Show Less

What listeners say about Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon